Type 2 Diabetes Clinical Trial
Official title:
Effect of Vitamin B12 Supplementation on Glycaemic Control in Uncontrolled Hyperhomocysteinemic Type 2 Diabetic Patients
Increased plasma homocysteine level is associated with macroangiopathy and nephropathy in
type 2 diabetes. Also increased levels of serum homocysteine are associated with
microalbuminuria which is associated with increased cardiovascular morbidity and mortality
among the patients with type 2 diabetes. With B12 supplementation homocysteine level can be
reduced .Type 2 diabetes as a metabolic syndrome may show improvement in glycaemic control
with Vitamin B12 therapy as there is correction of hyperhomocysteinemia. In studies it is
proved that combination of vit B12, folic acid and vit B6 are effective for
hyperhomocysteinemia.There are no such separate trials on the use of vit B12 alone. This
therapy may be used in large number of type 2 uncontrolled diabetic hyperhomocysteinemic
patients.
this study was planned with following objectives to study effect of Vitamin B12
supplementation on glycaemic control in poorly controlled hyperhomocysteinemic type 2
diabetic patients
1. Glycaemic control measured by levels of glycosylated haemoglobin (HbA1c) at baseline and
4 weeks
2. Fasting blood sugar level at baseline and 4 weeks
3. Serum homocysteine/ vitamin B12 levels at baseline and 4 weeks
4. Serum lipid profile at baseline and 4 weeks
After approval from Institutional Ethics Committee, patients not responding adequately to
oral anti-diabetic agents were recruited from Medicine out patient department (OPD) with the
help of treating physician. Patient were first screened for serum homocysteine/vitamin B12
level along with all baseline investigations. Those having serum homocysteine level more than
15 umol/L or vitamin B12 level less than 223pg/ml were enrolled in this study. Due to high
cost for investigation serum homocysteine level was measured only in 6 patients and serum
vitamin B12 level (cheaper test) was measured in 14 patients with prior permission from
Ethics Committee. Patients were given all the information about Vitamin B12 (methylcobalamin)
including adverse effects. A written informed consent was taken from each patient and those
who were willing to participate in study were enrolled in this study. All the information was
recorded in case report forms.
There were two groups of poorly controlled patient; one group (DRUG GROUP) received
methylcobalamin 500 ug daily with their usual antidiabetic therapy and the other group
(CONTROL GROUP) received suitable antidiabetic drug therapy as prescribed by treating
physician. Methylcobalamin 500ug was given once daily for the period of 4 weeks and were
followed-up at 4 weeks. At Baseline all the investigations were carried out as follows:
Study Flow Chart
Baseline Serum Homocysteine.n=6 (DRUG GROUP), Serum Vitamin B12, n=14 (DRUG GROUP), n=18
(CONTROL GROUP) Body weight, height, Blood pressure,glycosylated hemoglobin (HbA1c) level,
Blood sugar-Fasting/Postprandial, Serum lipid profile( to measure the effect of Vitamin B12),
Blood urea, Serum creatinine, Serum Bilirubin, Serum glutamate oxaloacetate transaminase
(SGOT),Serum glutamate pyruvate transaminase (SGPT), Alkaline phosphatase ( to rule out
hepatic or renal dysfunction ), Routine urine examination for albumin, Electrocardiogram
(ECG):to rule out cardiac abnormality viz, IHD, arrhythmias
4 Weeks Body weight, Blood pressure, glycosylated hemoglobin(HbA1c) level, Blood
sugar-Fasting/Postprandial, Serum lipid profile, Serum homocysteine/ serum vitamin B12, Urine
albumin examination
After enrollment of patient for study, All the baseline investigations will be carried out at
Central Clinical Laboratory except glycosylated haemoglobin which was carried out at
department of Pharmacology and homocysteine estimation which was carried out in an accredited
laboratory. ECG, Blood pressure recording was carried out in Department of Medicine.
Reporting of Adverse effects: All patients had been given checklist of adverse effect of
vitamin B12. Information of adverse drug reactions (ADRs ) was taken in next follow-up. If
patients are unable tolerate adverse drug reactions they were advised to contact any of
investigators at any time. Contact numbers of investigators was mentioned on patient
information sheet.
Expected adverse drug reactions of vitamin B12 : Anorexia, Nausea, Vomiting, Diarrhea and
Rash
Sample Size Calculation and statistical analysis:
Sample size of 20 for each group was calculated in the ratio of 1, power 80 %, considering 10
fold difference of drug effect in vitamin B12 group and control group by using Open Epi
2.3(2009). Randomization was done with the help of randomization software Rando 1.2,2004.
Statistical analysis was done by using Open Epi 2.3(2009) and Microsoft Excel.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05219994 -
Targeting the Carotid Bodies to Reduce Disease Risk Along the Diabetes Continuum
|
N/A | |
Completed |
NCT04056208 -
Pistachios Blood Sugar Control, Heart and Gut Health
|
Phase 2 | |
Completed |
NCT02284893 -
Study to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in Combination With Metformin Compared to Sitagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone
|
Phase 3 | |
Completed |
NCT04274660 -
Evaluation of Diabetes and WELLbeing Programme
|
N/A | |
Active, not recruiting |
NCT05887817 -
Effects of Finerenone on Vascular Stiffness and Cardiorenal Biomarkers in T2D and CKD (FIVE-STAR)
|
Phase 4 | |
Active, not recruiting |
NCT05566847 -
Overcoming Therapeutic Inertia Among Adults Recently Diagnosed With Type 2 Diabetes
|
N/A | |
Recruiting |
NCT06007404 -
Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
|
||
Completed |
NCT04965506 -
A Study of IBI362 in Chinese Patients With Type 2 Diabetes
|
Phase 2 | |
Recruiting |
NCT06115265 -
Ketogenic Diet and Diabetes Demonstration Project
|
N/A | |
Active, not recruiting |
NCT03982381 -
SGLT2 Inhibitor or Metformin as Standard Treatment of Early Stage Type 2 Diabetes
|
Phase 4 | |
Completed |
NCT04971317 -
The Influence of Simple, Low-Cost Chemistry Intervention Videos: A Randomized Trial of Children's Preferences for Sugar-Sweetened Beverages
|
N/A | |
Completed |
NCT04496154 -
Omega-3 to Reduce Diabetes Risk in Subjects With High Number of Particles That Carry "Bad Cholesterol" in the Blood
|
N/A | |
Completed |
NCT04023539 -
Effect of Cinnamomum Zeylanicum on Glycemic Levels of Adult Patients With Type 2 Diabetes
|
N/A | |
Recruiting |
NCT05572814 -
Transform: Teaching, Technology, and Teams
|
N/A | |
Enrolling by invitation |
NCT05530356 -
Renal Hemodynamics, Energetics and Insulin Resistance: A Follow-up Study
|
||
Completed |
NCT03960424 -
Diabetes Management Program for Hispanic/Latino
|
N/A | |
Completed |
NCT04097600 -
A Research Study Comparing Active Drug in the Blood in Healthy Participants Following Dosing of the Current and a New Formulation (D) Semaglutide Tablets
|
Phase 1 | |
Completed |
NCT05378282 -
Identification of Diabetic Nephropathy Biomarkers Through Transcriptomics
|
||
Active, not recruiting |
NCT06010004 -
A Long-term Safety Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes
|
Phase 3 | |
Completed |
NCT03653091 -
Safety & Effectiveness of Duodenal Mucosal Resurfacing (DMR) Using the Revita™ System in Treatment of Type 2 Diabetes
|
N/A |